Valgan (Valganciclovir) is an antiviral drug for the treatment of CMV retinitis in patients with AIDS, and for the prevention of CMV infections after organ transplantation. The active active ingredient of the drug is valganciclovir, which, after taking, due to the work of intestinal and hepatic esterases, immediately turns into ganciclovir.
Valgan’s action is based on suppressing the spread and multiplication of herpes viruses in vitro and in vivo. The activity of ganciclovir is based on suppressing the synthesis of infected DNA by incorporating it into the structure of viral DNA or by competitively inhibiting the incorporation into DNA molecules by viral polymerase.
Among human viruses sensitive to Valcyte, there are: CMV, herpes types 1, 2, 6, 7 and 8, Epstein-Barr viruses, chickenpox and hepatitis B.
The positive effect of Valgan was proved after studies, during which there was a decrease in the release of CMV from the body of the carrier of the infection from 47% to 7% after 1 month of taking the pills.
Valgan is contraindicated in a group of people under 12 years of age weighing less than 14 kg, during pregnancy and lactation, as well as in case of hypersensitivity to valganciclovir.